CLINICAL TRIALS PROFILE FOR ERGOCALCIFEROL
✉ Email this page to a colleague
All Clinical Trials for Ergocalciferol
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00114556 ↗ | The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients | Completed | Novartis | Phase 4 | 2000-02-01 | Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation. |
NCT00114556 ↗ | The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients | Completed | Royal Prince Alfred Hospital, Sydney, Australia | Phase 4 | 2000-02-01 | Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation. |
NCT00157066 ↗ | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Completed | Department of Clinical Biochemistry, Homerton Hospital, London E9 6SR, UK | N/A | 2002-12-01 | The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection. |
NCT00157066 ↗ | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Completed | Environmental Health Department, London Borough of Newham, London E15 4SF, UK | N/A | 2002-12-01 | The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection. |
NCT00157066 ↗ | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Completed | Imperial College London | N/A | 2002-12-01 | The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection. |
NCT00157066 ↗ | Effects of Vitamin D Supplementation on Antimycobacterial Immunity | Completed | Newham Chest Clinic, London E7 8QP, UK | N/A | 2002-12-01 | The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ergocalciferol
Condition Name
Clinical Trial Locations for Ergocalciferol
Trials by Country
Clinical Trial Progress for Ergocalciferol
Clinical Trial Phase
Clinical Trial Sponsors for Ergocalciferol
Sponsor Name
Sponsor Name for Ergocalciferol | |
Sponsor | Trials |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 |
Massachusetts General Hospital | 3 |
King Faisal Specialist Hospital & Research Center | 3 |
[disabled in preview] | 7 |
This preview shows a limited data set Subscribe for full access, or try a Trial |